NFIB and prostate cancer: Previous research indicates that SMAD3 is overexpressed in advanced prostate cancer tissues and promotes CRPC cell proliferation.[41] NFIB facilitates tumor cell proliferation and resistance in hormone‐dependent breast cancer and colorectal cancer.[42] NFIB is also identified to promote EMT and metastasis of CRPC.[43] Initially identified as an oncogene in B‐cell lymphoma, BCL6 drives malignant phenotypes by inhibiting proliferation and DNA damage checkpoints, while obstructing terminal B‐cell differentiation.